Johnson & Johnson/Omrix’s Evicel Approved For Use In Vascular Surgery
This article was originally published in The Pink Sheet Daily
Executive Summary
Partners anticipate first-quarter 2008 approval of liquid fibrin sealant for general hemostasis in surgery.
You may also be interested in...
Johnson & Johnson/Omrix Win General Surgery Hemostasis Approval For Evicel
Approval puts Evicel marginally ahead of ZymoGenetics’ recombinant human fibrin sealant rhThrombin, which has a Jan. 17 action date.
Johnson & Johnson/Omrix Win General Surgery Hemostasis Approval For Evicel
Approval puts Evicel marginally ahead of ZymoGenetics’ recombinant human fibrin sealant rhThrombin, which has a Jan. 17 action date.
FDA Extends ZymoGenetics’ rhThrombin Action Date To Jan. 17
ZymoGenetics and commercialization partner Bayer will use the three-month extension to hone plans for “aggressively converting the market,” firm tells “The Pink Sheet” DAILY.